Literature DB >> 22626821

Normal and pathologic concentrations of uremic toxins.

Flore Duranton1, Gerald Cohen, Rita De Smet, Mariano Rodriguez, Joachim Jankowski, Raymond Vanholder, Angel Argiles.   

Abstract

An updated review of the existing knowledge regarding uremic toxins facilitates the design of experimental studies. We performed a literature search and found 621 articles about uremic toxicity published after a 2003 review of this topic. Eighty-seven records provided serum or blood measurements of one or more solutes in patients with CKD. These records described 32 previously known uremic toxins and 56 newly reported solutes. The articles most frequently reported concentrations of β2-microglobulin, indoxyl sulfate, homocysteine, uric acid, and parathyroid hormone. We found most solutes (59%) in only one report. Compared with previous results, more recent articles reported higher uremic concentrations of many solutes, including carboxymethyllysine, cystatin C, and parathyroid hormone. However, five solutes had uremic concentrations less than 10% of the originally reported values. Furthermore, the uremic concentrations of four solutes did not exceed their respective normal concentrations, although they had been previously described as uremic retention solutes. In summary, this review extends the classification of uremic retention solutes and their normal and uremic concentrations, and it should aid the design of experiments to study the biologic effects of these solutes in CKD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22626821      PMCID: PMC3380651          DOI: 10.1681/ASN.2011121175

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  109 in total

Review 1.  An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations.

Authors:  John D Horowitz; Tamila Heresztyn
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-10-11       Impact factor: 3.205

2.  Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.

Authors:  B Bammens; P Evenepoel; H Keuleers; K Verbeke; Y Vanrenterghem
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612

3.  Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: Results from the STANISLAS cohort.

Authors:  Hind Berrahmoune; John V Lamont; Bernard Herbeth; Peter S FitzGerald; Sophie Visvikis-Siest
Journal:  Clin Chem       Date:  2006-01-19       Impact factor: 8.327

4.  Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis.

Authors:  Jacek Rysz; Maciej Banach; Aleksandra Cialkowska-Rysz; Robert Stolarek; Marcin Barylski; Jaroslaw Drozdz; Piotr Okonski
Journal:  Cell Mol Immunol       Date:  2006-04       Impact factor: 11.530

5.  Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis.

Authors:  Marcus A Bain; Randall Faull; Gianfranco Fornasini; Robert W Milne; Allan M Evans
Journal:  Nephrol Dial Transplant       Date:  2006-01-09       Impact factor: 5.992

6.  Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.

Authors:  Sophia Zoungas; Barry P McGrath; Pauline Branley; Peter G Kerr; Christine Muske; Rory Wolfe; Robert C Atkins; Kathy Nicholls; Margaret Fraenkel; Brian G Hutchison; Robert Walker; John J McNeil
Journal:  J Am Coll Cardiol       Date:  2006-02-23       Impact factor: 24.094

7.  Relationship between uremic toxins and oxidative stress in patients with chronic renal failure.

Authors:  Przemyslaw Rutkowski; Ewa Maria Słominska; Marek Szołkiewicz; Ewa Aleksandrowicz; Ryszard Tomasz Smolenski; Wojciech Wołyniec; Marcin Renke; Krystyna Wisterowicz; Julian Swierczynski; Boleslaw Rutkowski
Journal:  Scand J Urol Nephrol       Date:  2007

8.  Selective adsorption of homocysteine using an HFR-ON LINE technique.

Authors:  Giorgio Splendiani; Sandro De Angelis; Tiziana Tullio; Michele Ferranini; Maria Rita Dessì; Anna Pastore; Stefania Casciani; Laura Liberatoscioli; Giorgio Federici; Claudio Cortese
Journal:  Artif Organs       Date:  2004-06       Impact factor: 3.094

9.  Soluble adhesion molecules in end-stage renal disease: a predictor of outcome.

Authors:  Mohamed E Suliman; A Rashid Qureshi; Olof Heimbürger; Bengt Lindholm; Peter Stenvinkel
Journal:  Nephrol Dial Transplant       Date:  2006-02-13       Impact factor: 5.992

10.  Respective role of uraemic toxins and myeloperoxidase in the uraemic state.

Authors:  Chantal Capeillère-Blandin; Valérie Gausson; Anh Thu Nguyen; Béatrice Descamps-Latscha; Tilman Drüeke; Véronique Witko-Sarsat
Journal:  Nephrol Dial Transplant       Date:  2006-02-13       Impact factor: 5.992

View more
  304 in total

1.  Effect of uraemia on endothelial cell damage is mediated by the integrin linked kinase pathway.

Authors:  Andrea García-Jérez; Alicia Luengo; Julia Carracedo; Rafael Ramírez-Chamond; Diego Rodriguez-Puyol; Manuel Rodriguez-Puyol; Laura Calleros
Journal:  J Physiol       Date:  2014-12-18       Impact factor: 5.182

2.  What determines whether a patient initiates chronic renal replacement therapy?

Authors:  Michael J Germain; Lewis M Cohen
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-05       Impact factor: 8.237

3.  Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion.

Authors:  Tammy L Sirich; Benjamin A Funk; Natalie S Plummer; Thomas H Hostetter; Timothy W Meyer
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

4.  Extendin-4 protects kidney from acute ischemia-reperfusion injury through upregulation of NRF2 signaling.

Authors:  Yen-Yi Zhen; Chih-Chao Yang; Chi-Chih Hung; Chia-Chang Lee; Chen-Chang Lee; Chien-Hsing Wu; Yen-Ta Chen; Wei-Yu Chen; Kuan-Hung Chen; Hon-Kan Yip; Sheung-Fat Ko
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 5.  Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University.

Authors:  Nikolaus Marx; Heidi Noels; Joachim Jankowski; Jürgen Floege; Danilo Fliser; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2018-05-04       Impact factor: 5.460

Review 6.  The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.

Authors:  Raymond Vanholder; Eva Schepers; Anneleen Pletinck; Evi V Nagler; Griet Glorieux
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

Review 7.  Approaches to uremia.

Authors:  Timothy W Meyer; Thomas H Hostetter
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

8.  Genome-Wide Association Studies of Metabolites in Patients with CKD Identify Multiple Loci and Illuminate Tubular Transport Mechanisms.

Authors:  Yong Li; Peggy Sekula; Matthias Wuttke; Judith Wahrheit; Birgit Hausknecht; Ulla T Schultheiss; Wolfram Gronwald; Pascal Schlosser; Sara Tucci; Arif B Ekici; Ute Spiekerkoetter; Florian Kronenberg; Kai-Uwe Eckardt; Peter J Oefner; Anna Köttgen
Journal:  J Am Soc Nephrol       Date:  2018-03-15       Impact factor: 10.121

9.  Urea impairs β cell glycolysis and insulin secretion in chronic kidney disease.

Authors:  Laetitia Koppe; Elsa Nyam; Kevin Vivot; Jocelyn E Manning Fox; Xiao-Qing Dai; Bich N Nguyen; Dominique Trudel; Camille Attané; Valentine S Moullé; Patrick E MacDonald; Julien Ghislain; Vincent Poitout
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

Review 10.  Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.

Authors:  Alexander J Prokopienko; Thomas D Nolin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-09-20       Impact factor: 5.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.